Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients: a five-year report.
A controlled clinical trial of two multidrug regimens in multibacillary lepromatous and near-lepromatous patients with a bacterial index (BI) of 2.5 or more was conducted. Patients were randomly allocated to either a two-drug regimen of dapsone plus clofazimine for 60 months or a four-drug regimen of rifampin, isoniazid, dapsone, and clofazimine for the first 3 months and clofazimine plus dapsone for the next 57 months. There was no difference between the rifampin and nonrifampin regimens with respect to the clinical improvement or bacteriological status of the patients at 60 months. Reactive states and neuritis were observed to be equal in the two patient groups.
Thomas
A
A
Tuberculosis Research Centre, Madras, India.
Balakrishnan
A
A
Nagarajan
M
M
Prabhakar
R
R
Tripathy
S P
SP
Christian
M
M
Somasundaram
P R
PR
D000293:Adolescent; D000328:Adult; D002991:Clofazimine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007538:Isoniazid / Q000627:therapeutic use; D007917:Leprostatic Agents / Q000627:therapeutic use*; D015439:Leprosy, Borderline / Q000188:drug therapy*; D015440:Leprosy, Lepromatous / Q000188:drug therapy*; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012293:Rifampin / Q000627:therapeutic use*
D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine; D007538:Isoniazid; D012293:Rifampin